Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Non Operating Income (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Non Operating Income for 11 consecutive years, with -$508000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 330.51% to -$508000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$715000.0 through Dec 2025, down 261.11% year-over-year, with the annual reading at -$824000.0 for FY2025, 166.67% down from the prior year.
  • Non Operating Income hit -$508000.0 in Q4 2025 for Guided Therapeutics, down from -$257000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $555000.0 in Q3 2021 to a low of -$508000.0 in Q4 2025.
  • Historically, Non Operating Income has averaged -$57555.6 across 5 years, with a median of -$50000.0 in 2023.
  • Biggest five-year swings in Non Operating Income: plummeted 2800.0% in 2023 and later skyrocketed 9700.0% in 2025.
  • Year by year, Non Operating Income stood at -$9000.0 in 2021, then surged by 222.22% to $11000.0 in 2022, then surged by 1445.45% to $170000.0 in 2023, then tumbled by 169.41% to -$118000.0 in 2024, then plummeted by 330.51% to -$508000.0 in 2025.
  • Business Quant data shows Non Operating Income for GTHP at -$508000.0 in Q4 2025, -$257000.0 in Q3 2025, and -$48000.0 in Q2 2025.